JP2008516985A5 - - Google Patents

Download PDF

Info

Publication number
JP2008516985A5
JP2008516985A5 JP2007537014A JP2007537014A JP2008516985A5 JP 2008516985 A5 JP2008516985 A5 JP 2008516985A5 JP 2007537014 A JP2007537014 A JP 2007537014A JP 2007537014 A JP2007537014 A JP 2007537014A JP 2008516985 A5 JP2008516985 A5 JP 2008516985A5
Authority
JP
Japan
Prior art keywords
seq
polypeptide
antibody
zcytor21
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007537014A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008516985A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/037332 external-priority patent/WO2006044840A2/en
Publication of JP2008516985A publication Critical patent/JP2008516985A/ja
Publication of JP2008516985A5 publication Critical patent/JP2008516985A5/ja
Pending legal-status Critical Current

Links

JP2007537014A 2004-10-18 2005-10-18 可溶性zcytor21、抗zcytor21抗体及び結合パートナー、並びに炎症における使用方法 Pending JP2008516985A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61965104P 2004-10-18 2004-10-18
US62220704P 2004-10-25 2004-10-25
PCT/US2005/037332 WO2006044840A2 (en) 2004-10-18 2005-10-18 Soluble zcytor21, anti-zcytor21 antibodies and binding partners and methods of using in inflammation

Publications (2)

Publication Number Publication Date
JP2008516985A JP2008516985A (ja) 2008-05-22
JP2008516985A5 true JP2008516985A5 (cg-RX-API-DMAC7.html) 2008-12-11

Family

ID=36090952

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007537014A Pending JP2008516985A (ja) 2004-10-18 2005-10-18 可溶性zcytor21、抗zcytor21抗体及び結合パートナー、並びに炎症における使用方法

Country Status (12)

Country Link
US (3) US20060142192A1 (cg-RX-API-DMAC7.html)
EP (1) EP1802657A2 (cg-RX-API-DMAC7.html)
JP (1) JP2008516985A (cg-RX-API-DMAC7.html)
KR (1) KR20070084330A (cg-RX-API-DMAC7.html)
AU (1) AU2005295421A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0516603A (cg-RX-API-DMAC7.html)
CA (1) CA2584078A1 (cg-RX-API-DMAC7.html)
EA (1) EA200700823A1 (cg-RX-API-DMAC7.html)
IL (1) IL182186A0 (cg-RX-API-DMAC7.html)
MX (1) MX2007004597A (cg-RX-API-DMAC7.html)
NO (1) NO20072514L (cg-RX-API-DMAC7.html)
WO (1) WO2006044840A2 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040197306A1 (en) * 2000-05-24 2004-10-07 Gorman Daniel M. Mammalian receptor proteins; related reagents and methods
EA200700823A1 (ru) * 2004-10-18 2008-02-28 Займодженетикс, Инк., Сша Растворимый zcytor21, анти-zcytor21 антитела и связывающие партнёры и способы применения при воспалении
CA2624763A1 (en) * 2005-10-18 2007-04-26 Zymogenetics, Inc. Il-17c antagonists and methods of using the same
WO2008049070A2 (en) * 2006-10-18 2008-04-24 Zymogenetics, Inc. Il-17c antagonists and methods of using the same
HUE037087T2 (hu) 2011-10-19 2018-08-28 Morphosys Ag IL17C antagonistái gyulladásos rendellenességek kezelésére
EP3359161A1 (en) 2015-10-05 2018-08-15 MorphoSys AG Antagonists of il-17c for the treatment and/or prevention of atopic dermatitis
MA44227B1 (fr) 2016-02-19 2021-06-30 Galapagos Nv Anticorps pour il-17c
IL309179A (en) * 2021-06-10 2024-02-01 Janssen Biotech Inc Nucleic acid coding for KLK2-GPI fusion protein, recombinant cells and their uses

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869286A (en) * 1995-03-23 1999-02-09 Immunex Corporation Receptor that binds IL-17
US20020177188A1 (en) * 1998-05-15 2002-11-28 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US6579520B2 (en) * 1998-05-15 2003-06-17 Genentech, Inc. IL-17 related mammalian cytokine polypeptides (IL-17E)
US6569645B2 (en) * 1999-05-14 2003-05-27 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
AU2001274920A1 (en) * 2000-05-24 2001-12-03 Schering Corporation Mammalian receptor proteins; related reagents and methods
US20040197306A1 (en) * 2000-05-24 2004-10-07 Gorman Daniel M. Mammalian receptor proteins; related reagents and methods
US20030096969A1 (en) * 2000-06-02 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2005508615A (ja) * 2001-07-09 2005-04-07 ザイモジェネティクス,インコーポレイティド ヒトサイトカイン受容体
EA200700823A1 (ru) * 2004-10-18 2008-02-28 Займодженетикс, Инк., Сша Растворимый zcytor21, анти-zcytor21 антитела и связывающие партнёры и способы применения при воспалении
CA2624763A1 (en) * 2005-10-18 2007-04-26 Zymogenetics, Inc. Il-17c antagonists and methods of using the same

Similar Documents

Publication Publication Date Title
CN105968204B (zh) 一种抗前列腺特异性膜抗原的单域重链抗体
CN111303279A (zh) 一种针对新型冠状病毒的单域抗体及其应用
JP2009197002A5 (cg-RX-API-DMAC7.html)
AU2012205384B2 (en) IL-27 antagonists for treating inflammatory diseases
RU2010151725A (ru) Аминокислотные последовательности, направленные против cхcr4 и других gpcr, и соединения, включаюшие их
EA201370105A1 (ru) Человеческие антитела против человеческого tnf-подобного лиганда-1а (tl1a)
JP2008508882A5 (cg-RX-API-DMAC7.html)
JP2019510739A5 (cg-RX-API-DMAC7.html)
JP2012012402A5 (cg-RX-API-DMAC7.html)
JP2002542157A5 (cg-RX-API-DMAC7.html)
CN105968201A (zh) 针对前列腺特异性膜抗原的单域重链抗体
JP2014500862A5 (cg-RX-API-DMAC7.html)
JP2016509585A5 (cg-RX-API-DMAC7.html)
JP2008517922A5 (cg-RX-API-DMAC7.html)
JP2005528884A5 (cg-RX-API-DMAC7.html)
JP2010500380A5 (cg-RX-API-DMAC7.html)
JP2008516985A5 (cg-RX-API-DMAC7.html)
CN105968203A (zh) 一种抗前列腺特异性膜抗原胞外区的单域重链抗体
EP2984108A1 (en) Anti-s100a7 antibodies for the treatment and diagnosis of cancer
CN105968205A (zh) 一种抗前列腺特异性膜抗原的纳米抗体
Santulli-Marotto et al. Surrogate antibodies that specifically bind and neutralize CCL17 but not CCL22
CN105524170A (zh) 能特异结合前列腺特异性膜抗原的纳米抗体
JP2010521139A5 (cg-RX-API-DMAC7.html)
JP2010503687A5 (cg-RX-API-DMAC7.html)
Antoine et al. Isolation of SARS-CoV-2-blocking recombinant antibody fragments and characterisation of their binding to variant spike proteins